Aptamer Group to publish full year results on 22 October 2024

Aptamer Group plc (LON: APTA) trading update for H1 25 highlights progress in key asset development programmes, including promising Unilever deodorant trials.

Aptamer Group plc (LON: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced three new members to its Scientific Advisory Board (SAB).   Dr Paloma Giangrande, Dr Louis Allot, and Dr Adam

Aptamer Group plc (LON: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that Dr Arron Tolley, Chief Executive Officer and Dr David Bunka, Chief Scientific Officer will be hosting a

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will hold its Annual General Meeting (AGM) at 10:00 am today at the offices of Aptamer Group, Windmill House, Innovation

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that a genetic medicines customer has selected to progress to the final commercial development phase for Optimer delivery

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has provided an update on contracts signed since its financial year ended 30 June 2024. Aptamer has secured new contracts

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced its full year results for the twelve months ended 30 June 2024. Highlights ·      New strategic approach launched in August

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced the appointment of Tim Sykes to its Board of Directors as a Non-Executive Director with immediate effect. Tim

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that it has conditionally raised £2.83 million (before expenses),  by way of a placing and subscription of